Genmab shares jumped 7% in Friday morning trading on the Copenhagen Stock Exchange, adding approximately DKK 9 billion to the company's market capitalization.
The sharp move reflects sustained investor enthusiasm following the biotechnology firm's decision to raise its revenue guidance for the year.
Shares had previously climbed approximately 7% in Tuesday trading after the company released robust results from a pivotal Phase 3 clinical trial.
The Danish company cited stronger-than-expected sales performance across several of its cancer treatments as the primary driver for the upward revision.
This commercial acceleration marks a positive shift for the firm, which has been working to expand the market penetration of its monoclonal antibody portfolio.
The rally builds on recent positive sentiment surrounding Genmab.
Shares had previously climbed approximately 7% in Tuesday trading after the company released robust results from a pivotal Phase 3 clinical trial.